NCT04284631View on ClinicalTrials.gov

Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.

CompletedOBSERVATIONAL

Enrollment

54

Participants

Timeline

Start Date

January 1, 2012

Primary Completion Date

December 30, 2014

Study Completion Date

December 30, 2019

Conditions

Ovarian Cancer

All Listed Sponsors

lead

Port Said University hospital

OTHER

NCT04284631 - Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma. | Biotech Hunter | Biotech Hunter